These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 782698)

  • 21. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
    Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
    Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
    Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol.
    Carella AM; Carlier P; Congiu A; Occhini D; Nati S; Santini G; Pierluigi D; Giordano D; Bacigalupo A; Damasio E
    Bone Marrow Transplant; 1991 Aug; 8(2):99-103. PubMed ID: 1718517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
    Seropian S; Nadkarni R; Jillella AP; Salloum E; Burtness B; Hu GL; Zelterman D; Cooper DL
    Bone Marrow Transplant; 1999 Mar; 23(6):599-605. PubMed ID: 10217191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
    Hansen HH; Selawry OS; Pajak TF; Spurr CL; Falkson G; Brunner K; Cuttner J; Nissen NI; Holland JF
    Cancer; 1981 Jan; 47(1):14-8. PubMed ID: 7006789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of mycosis fungoides with topical BCNU.
    Zackheim HS; Epstein EH; Grekin DA
    Cancer Treat Rep; 1979 Apr; 63(4):623. PubMed ID: 156070
    [No Abstract]   [Full Text] [Related]  

  • 31. Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's disease.
    DeConti RC; Mitchell MS; Marsh JC; Bertino JR
    Cancer Chemother Rep; 1971 Dec; 55(5):607-10. PubMed ID: 4946083
    [No Abstract]   [Full Text] [Related]  

  • 32. Toxicity study of BCNU (NSC-409962) given orally.
    Lessner HE; Vogler WR
    Cancer Chemother Rep; 1974; 58(3):407-11. PubMed ID: 4601671
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Marsh JC; DeConti RC; Hubbard SP
    Cancer Chemother Rep; 1971 Dec; 55(5):599-606. PubMed ID: 4334161
    [No Abstract]   [Full Text] [Related]  

  • 34. Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results.
    Presant CA; Klahr C; Olander J; Gatewood D
    Cancer; 1976 Nov; 38(5):1917-21. PubMed ID: 991105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trial of BCNU (NSC-409962) combined with vincristine (NSC-67574) in disseminated gastrointestinal cancer and other neoplasms.
    Stolinsky DC; Pugh RP; Bohannon RA; Bogdon DL; Bateman JR
    Cancer Chemother Rep; 1974; 58(6):947-50. PubMed ID: 4614902
    [No Abstract]   [Full Text] [Related]  

  • 36. H2-antagonists and carmustine.
    Dorr RT; Soble MJ
    J Cancer Res Clin Oncol; 1989; 115(1):41-6. PubMed ID: 2564000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1.3 Bis-(2 chloroethyl)-1-nitrosourea and streptozotocin chemotherapy.
    Lokich JJ; Chawla PL; Frei E
    Clin Pharmacol Ther; 1975 Mar; 17(3):374-8. PubMed ID: 123490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II clinical trials of BCNU )NSC-409962) and bleomycin (NSC-125066) in the treatment of Kaposi's sarcoma.
    Vogel CL; Clements D; Wanume AK; Toya T; Primack A; Kyalwazi S
    Cancer Chemother Rep; 1973; 57(3):325-33. PubMed ID: 4127394
    [No Abstract]   [Full Text] [Related]  

  • 39. BCNU (1,3,bis(B-chloroethyl)-1-nitrosourea. Effects on advanced Hodgkin's disease and other neoplasia.
    Lessner HE
    Cancer; 1968 Aug; 22(2):451-6. PubMed ID: 4873194
    [No Abstract]   [Full Text] [Related]  

  • 40. Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.
    Coltman CA; McDaniel TM; Balcerzak SP; Morrison FS; Von Hoff DD
    Invest New Drugs; 1983; 1(1):65-70. PubMed ID: 6678857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.